In this article
- Lancet Study Reveals Superior Treatment Regimen for CD30-Positive Peripheral T-Cell Lymphoma
- Phase 3 Clinical Trial Design and Patient Population
- A Plus CHP Demonstrates Nearly Double Progression Free Survival Compared to CHOP
- New Standard Treatment Established for CD30-Positive Peripheral T-Cell Lymphoma
- How CancerFax Helps
12 Yue 3 days, a study "The Lancet" published online, for CD30-positive outer peripheral T-cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone (A + CHP) Better than cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
Steven Horwitz, MD, from the Memorial Sloan Kettering Cancer Center in New York City and colleagues conducted a double-blind, placebo-controlled, active-control phase 3 study involving 452 patients from 132 locations in 17 countries. These patients CD30-positive peripheral T-cell lymphoma without prior treatment. Patients with 1:1 random allocation ratio, accepts A + CHP or of CHOP, sustained 6, or. 8 th 21 is day cycle
The researchers found that the median progression-free survival (PFS) of the A + CHP group and the CHOP group were 48.2 and 20.8 months, respectively. The incidence of side effects was similar between the two groups, including febrile neutropenia (18% and 15%, respectively) and peripheral neuropathy (52% and 55%, respectively). Fatal adverse events occurred in 3% and 4% of patients, respectively.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma patients.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.